Option chain shows key data for Scopus BioPharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Scopus BioPharma.

Scopus BioPharma (OTC:SCPS) Stock, Option Chain

Scopus BioPharma

Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACMR

AEHR

ALVO

AMPX

ATNF

AVYA

BXRX

CACO

CENN

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

Core Scientific, Inc. - Class A Common Stock

CORZ

CVNA

DATS

EDSA

EVLV

GROM

GRRR

HLGN

HSDT

IMRN

LANV

LIPO

LWLG

MGAM

MLKN

OGEN

ORIC

OXBR

PBTS

PLXP

PRQR

RCKT

REKR

SAVA

SCPS

SINT

SOLO

Sunlight Financial Holdings, Inc. Class A Common Stock

SUNL

UIHC

VEDU

VERO

WEST

WETG

WISH

Gainers


	Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.


Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday&#39;s Mid-Day Session

ACLX

AGFY

AKLI

AKRO

ANEB

ANTE

APPH

ARBK

ARDX

ASPU

AXLA

BRDS

CCCC

CELC

CERE

CHPT

CINT

COEP

COSM

CZOO

DOMO

ETNB

FTFT

GEVO

GOSS

GREE

HCTI

HLTH

ICPT

IPDN

IPHA

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MDGL

MHUA

MINM

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

MOND

MRSN

MULN

NEPT

NEWP

NEXA

NOGN

OBSV

OTIC

PERF

PHGE

PRFX

QUMU

RDIB

RELL

RLAY

SEER

SLNO

SMMT

SNPX

TELL

TERN

TRKA

VANI

VKTX

VTGN

ZVSA

Gainers


	Madrigal Pharmaceuticals, Inc.  (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.


Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday&#39;s Mid-Day Session

ADAG

ADBE

AGYS

ALLR

AMAM

AMEH

AUID

AUVI

BVXV

BYSI

CETX

CJJD

COIN

COMS

CRKN

DNUT

DRMA

New Oriental Education & Technology Group

Euda Health Holdings Limited - Ordinary Shares

EUDA

EXAS

FCUV

FFIE

ICVX

MAXR

MLGO

Morgan Stanley Capital Protected Notes for S&P 500 Index

NCRA

NVAX

PHIO

RCRT

SBET

SCHL

SPRY

STRY

STSS

TGTX

VLON

Gainers


	Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.


Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday&#39;s Mid-Day Session

SCOPUS BIOPHARMA INC by Scopus Biopharma, Inc.

Scopus BioPharma Inc

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

ABUS

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

ALDX

Aldeyra Therapeutics Announces FDA Acceptance For Review Of The Resubmitted New Drug Application For Reproxalap In Treatment Of Dry Eye Disease; Based On FDA Acceptance, Co. Announces Expansion Of Option Agreement With AbbVie

Biotech

Earnings

Guidance

Health Care

General

CLRB

Cellectar Biosciences' Q3 Cash And Cash Equivalents Of $34.3M Is Expected To Provide Cash Runway Into Q2 2025

Jefferies analyst Maury Raycroft initiates coverage on Erasca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>) with a Buy rating and announces Price Target of $6.

Initiation

ERAS

Jefferies Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $6

HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that they have entered into a worldwide exclusive license agreement to develop and commercialize one of HCWB's product candidates generated with its new drug discovery platform for therapeutic use.
Key terms of the agreement include that WY Biotech has agreed to pay HCWB $7.0 million in an upfront payment, and HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. In addition, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering.

HCWB

HCW Biologics Enters Exclusive Licensing Deal with WY Biotech for Immunotherapy Development

Jefferies analyst Surinder Thind initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $28.

INGM

Jefferies Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $28

Needham analyst James Ricchiuti maintains Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) with a Buy and raises the price target from $79 to $95.

BELFB

Needham Maintains Buy on Bel Fuse, Raises Price Target to $95

Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ongoing Phase 1/2 RESET-Myositis&#x2122;, RESET-SLE&#x2122; and RESET-SSc&#x2122; clinical trials. These data were presented in oral and poster presentations at the American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. Presentation materials featured at ACR Convergence 2024 can be accessed on the Company's website <a href="https://www.globenewswire.com/Tracker?data=NuB6bQJy6vE4R3OJFuE3vuxsoEvSwrwTyUPI4fvYmIBT0fvL012yVTAn9S9Yo8LyN19qNwjGHz6igro953l94X3M59TLKikZQzitchedLPtNyy589YOrDdQygeY7PaRT">here</a>.
"The clinical data reported at ACR Convergence this weekend support the potential of the current dose of CABA-201 to provide immunosuppressant-free, compelling clinical responses in patients with active, refractory autoimmune disease. Data presented from the previously reported patient with lupus nephritis who experienced ICANS and had acute inflammatory events shortly before CABA-201 treatment demonstrated an abnormal, pro-inflammatory cytokine profile prior to and after CABA-201 infusion, suggestive of an occult infection. As a result of these data, subjects in the RESET clinical program who develop a fever prior to scheduled infusion will wait a minimum of two weeks before administration of CABA-201. Other than this patient with a second, later peak expansion, CABA-201 displayed a consistent PK and PD profile in all other patients," said David J. Chang, M.D., Chief Medical Officer of Cabaletta. "In addition to our promising clinical and translational data set from the RESET program, we believe our efficient clinical trial design, growing footprint of 40 actively recruiting U.S. clinical sites and anticipated expansion into Europe in 2025 provide us with a differentiated opportunity to accelerate development of CABA-201 for patients. Data permitting, we anticipate meeting with the FDA in 2025 to discuss potential registrational trial designs for CABA-201 that will allow us to bring the therapeutic potential of this investigational therapy closer to autoimmune patients."
Cabaletta designed CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, to deeply and transiently deplete CD19-positive B cells following a one-time infusion that may enable a reset of the immune system with the potential for durable remission without chronic immunosuppressive therapies in patients with autoimmune diseases. Cabaletta is currently evaluating CABA-201 in the RESET clinical development program across five company-sponsored clinical trials that each have disease-specific cohorts with six patients per cohort. All cohorts are evaluating the same single, weight-based dose of CABA-201 at 1 x 106&nbsp;cells/kg without a dose escalation requirement. Treatment with CABA-201 in each clinical trial includes a preconditioning regimen of fludarabine and cyclophosphamide, consistent with the dosing regimen used in the third-party academic studies, except for the RESET-PV&#x2122; trial which is evaluating CABA-201 without preconditioning.

CABA

Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials

Fiscal 2025 Guidance:
<ul>
<li>The Company's Adjusted Diluted EPS&#x2A; guidance for the year ending July 31, 2025 remains unchanged at $4.40 to $4.70 per share, and the Company's GAAP earnings per diluted Class A Nonvoting Common Share guidance for the year ending July 31, 2025, was updated for amortization and other acquisition-related charges to $4.02 to $4.32 per share.</li>
<li>The other assumptions included in our fiscal 2025 guidance are effectively unchanged. We expect a full-year income tax rate of approximately 20 percent, depreciation and amortization expense of approximately $40 million, and capital expenditures of approximately $35 million. Our fiscal 2025 guidance is based on foreign currency exchange rates as of October 31, 2024, and assumes continued economic growth.</li>
</ul>

Brady Sees 2025 Adj EPS Guidance Of $4.40-$4.70 Vs. $4.59 Est.

Comments

Scopus BioPharma

Scopus BioPharma (SCPS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga